display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer HER 2 negative
es-BC - HER2 negative - (neo)adjuvant (NA)mBC - HER 2 negative
anti-PD-(L)1
durvalumab based treatment
durvalumab alone Saphir02 Breast-Immuno
pembrolizumab based treatment
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide I-SPY2

Study type: